Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Daniel A. Pollyea, Anagha Inguva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:805-811
The use of venetoclax in combination with hypomethylating agents (HMA) has changed the paradigm for the treatment of acute myeloid leukemia (AML) in elderly patients and those unfit for intensive chemotherapy. A phase 3 study has shown superior respo
Autor:
Theodore Argyrakos, Dimitrios Galopoulos, John V. Asimakopoulos, Panagiotis Toulas, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, Kostas Konstantopoulos, Stavrianna Diavati, Iliana Konstantinou
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e601-e605
Clinical Practice Points • Progressive multifocal leukoencephalopathy (PML) is a rare but fatal demyelinating disease caused by John Cunningham polyomavirus, mainly affecting immunosuppressed patients. It sporadically complicates hematological mali
Autor:
Tulika Seth, Manoranjan Mahapatra, Sudip Kumar Datta, Gopila Gupta, Ashish Datt Upadhyay, Richa Juneja, Vikas Garg, Renu Saxena
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e99-e104
Tumor lysis syndrome (TLS) is a metabolic emergency in hematology patients. The recommended dose of rasburicase for the management of TLS is 0.2 mg/kg per day for 5 days, which is cost prohibitive for many patients. We sought to determine the efficac
Autor:
Rupa Narayan, Thomas Martin, Mimi Lo, Ann A. Lazar, Marisela Tan, Sandy W. Wong, Sarah Kim, Nina Shah, Derek Galligan, Richard Fong, Jeffrey L. Wolf, Shagun Arora
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e961-e985
Although novel agents have changed the treatment landscape of multiple myeloma (MM), cytotoxic chemotherapy regimens continue to have a role in aggressive or rapidly progressive disease. In such cases, our institution has utilized a hyperfractionated
Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future
Autor:
Marlise R. Luskin, Daniel J. DeAngelo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S44-S47
Autor:
Robert M. Dean, Muhammad Junaid Tariq, Faiz Anwer, Aqsa Ashraf, Malik Qistas Ahmed, Talha Bin Farooq, Arafat Ali Farooqui, Muhammad Salman Faisal, Shaha Nabeel, Abraham S. Kanate, Ahmad Anjum, Saif Ur Rehman, Arshia Akbar
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e414-e426
Chronic lymphocytic leukemia (CLL) typically affects older patients; administration of traditional cytotoxic therapies in old patients has very modest benefit with no survival improvement. With better understanding of CLL biology, trends are shifting
Autor:
Yu Yagi, Eriko Nakashima, Motohiko Ikeda, Yoshimichi Tachikawa, Eriko Fujioka, Takamitsu Matsushima, Hayato Utsunomiya, Youko Suehiro, Tatsuro Goto, Akiko Takamatsu, Hiroshi Takatsuki, Hirofumi Ohno, Taisuke Narazaki, Hiroki Muta, Makoto Oyama, Akie Hirata, Mariko Tsuda, Mitsuo Kozuru, Yuji Yufu, Ilseung Choi, Naokuni Uike, Emi Tanaka, Shojiro Haji, Kaname Miyashita, Junichi Kiyasu, Yasuhiro Tsukamoto, Yasuhiro Nakashima
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e445-e453
Background We retrospectively analyzed patients with untreated aggressive adult T-cell leukemia/lymphoma who received the modified EPOCH (mEPOCH) regimen. Patients and Methods Patients received up to 6 mEPOCH cycles. Etoposide (50 mg/m2/day), doxorub
Autor:
Ling Zhang, Alan F. List, Rami S. Komrokji, Jeffrey E. Lancet, Sheng Wei, David A. Sallman, Pearlie K. Epling-Burnette, Adam W. Mailloux, Eric Padron, Javier Pinilla-Ibarz, Lisa A Nardelli, Sara Tinsley
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:157-161
Introduction: Recent studies emphasized the role of immune dysregulation and innate immune activation in the pathogenesis of myelodysplastic syndromes (MDS). The expansion of T-regulatory cells, namely effector memory cells (Treg EM), in MDS correlat
Autor:
Anne W. Beaven, David J. Adams, Benjamin Heyman, Joseph O. Moore, David A. Rizzieri, Carlos M. de Castro, Zhiguo Li, Louis F. Diehl
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:679-686
Background For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity.
Autor:
Todd A. Fehniger, Steven M. Devine, Samantha Jaglowski, Nancy L. Bartlett, Lai Wei, Mitch A. Phelps, Beth A. Christian, Xiaohua Zhu, Jennifer Sexton, Joseph Maly, Nina D. Wagner-Johnston, Kristie A. Blum
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:347-353
Background Lenalidomide and panobinostat have shown single-agent efficacy of 14% to 50% and 27% to 58%, respectively, in Hodgkin lymphoma (HL). This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of